▲ Professor Sung-Bae Kim of the Division of Oncology from Asan Medical Center delivers an oral presentation at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO).

Medical professionals from the Division of Oncology from Asan Medical Center presented a range of research findings on cancer treatment strategies at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, held in Chicago from May 30 to June 3. ASCO is the world’s most prestigious oncology conference, bringing together more than 40,000 cancer treatment specialists to share the latest cancer therapies and research trends.

At the conference, Professors Sung-Bae Kim and Hyehyun Jeong delivered an oral presentation titled “Phase III of Oral Paclitaxel (DHP107) vs. Intravenous Paclitaxel in HER2-Negative Recurrent or Metastatic Breast Cancer (mBC): Primary Analysis of Multinational OPTIMAL Trial.” Professors Min-Hee Ryu and Hyung-Don Kim presented “Artificial intelligence-based prediction of claudin 18.2 expression and immune phenotype to guide treatment decisions in patients with gastric cancer.” Professor Jae Lyun Lee presented “Combination casdatifan plus cabozantinib expansion cohort of phase 1 ARC-20 study in previously treated patients with clear cell renal cell carcinoma” and “Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC).” Professor Changhoon Yoo presented “RHEA-1: First-in-human (FIH) study of AZD9793, a first-in-class CD8-guided T cell-engager (TCE) for glypican-3-positive (GPC3+) advanced or metastatic hepatocellular carcinoma (HCC)” and “Clinical implication of MDM2 amplification in advanced biliary tract cancer (BTC): A propensity score-matched, retrospective cohort study of 813 patients.” Clinical Fellow Yeong Hak Bang presented “Artificial intelligence-powered spatial analysis of tumor microenvironment in non-small cell lung cancer patients who acquired resistance after EGFR tyrosine kinase inhibitors.”